Tumorimmuntherapy associated neurological adverse events
Recruiting
- Conditions
- Y57.9Drug or medicament, unspecified
- Registration Number
- DRKS00012668
- Lead Sponsor
- Charité Campus Charité Mitte
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Treatment with immune checkpoint inhibitor
Exclusion Criteria
Not able to consent. Persons under official or judicial custody. Contraindications for blood draw.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method First clinical presentation of a neurological irAE during the observation period of 12 months after treatment initiation.
- Secondary Outcome Measures
Name Time Method Sub-clinical signs of a neurological irAE